Last reviewed · How we verify
NCT06857136: GLINFANPH_2021
The Role of the Glymphatic System Avaluated Thourgh mr Imaging in the Diagnosis and Management of NPH
trial in Hydrocephalus in 29 participants. Completed in 31 December 2024.
31 August 2024
Quick facts
| Lead sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 15 June 2021 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Italy |
Conditions studied
- Hydrocephalus — all drugs for Hydrocephalus →
- Normal Pressure Hydrocephalus — all drugs for Normal Pressure Hydrocephalus →
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full company profile →
Who can join
50 and older, any sex, with Hydrocephalus or Normal Pressure Hydrocephalus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate the role of DTI-ALPS in the diagnostic and therapeutic management of NPH The main questions it aims to answer are: * Whether the glymphatic system (GS) is actually impaired in NPH * Whether DTI-ALPS index can predict the positive response to tap test (TT) and to ventriculo-peritoneal shunt (VPS) surgery. A healthy control group of patients (HC group) matched for age with the study group, will undergo MR with DTI-ALPS study
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06857136
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hydrocephalus
Currently open trials in the same condition.
- NCT07478926 — Flow Detection in Open and Closed Shunt Valve Periods · NA · recruiting
- NCT07442929 — Crystallization of LA and Adjuvant Mixtures in Cerebrospinal Fluid · recruiting
- NCT06797219 — Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4 · NA · recruiting
- NCT07380477 — VentricuLostomy AssoCiaTed InfeCtions (LACTIC): Focus on CSF Lactate and Sampling Site · recruiting
- NCT06276543 — Bactiseal Catheter Safety Registry Study · recruiting
Other Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials
Trials by the same sponsor.
- NCT07168850 — Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia · NA · recruiting
- NCT06699095 — Home Rehabilitation As Continuity of Care in MS · NA · recruiting
- NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
- NCT06584097 — COMparative Performance of General Purpose Models · recruiting
- NCT07427940 — Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06857136 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06857136.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing